Similar articles

• Hyperacute skin allograft rejection in presensitized rats is abrogated by malononitrilamides.

  Schorlemmer HU, Kurrle R. Schorlemmer HU, et al. Transplant Proc. 1998 Jun;30(4):963-7. doi: 10.1016/s0041-1345(98)00112-2. Transplant Proc. 1998. PMID: 9636390 No abstract available.
• Rapamycin abrogates accelerated rejection in sensitized rats by selectively suppressing intragraft cell activation, adhesion/binding properties, and modulating serum alloantibody responses.

  Schmidbauer G, Hancock WW, Wasowska B, Binder J, Padberg W, Kupiec-Weglinski JW. Schmidbauer G, et al. Transplant Proc. 1995 Feb;27(1):427-9. Transplant Proc. 1995. PMID: 7879048 No abstract available.
• Leflunomide prolongs pulmonary allograft and xenograft survival.

  Yuh DD, Gandy KL, Morris RE, Hoyt G, Gutierrez J, Reitz BA, Robbins RC. Yuh DD, et al. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 1):1136-44. J Heart Lung Transplant. 1995. PMID: 8719461
• Tolerance or accommodation: the lesson from leflunomide.

  Sebille F, Dorling A. Sebille F, et al. Transplantation. 2005 Jan 27;79(2):133-4. doi: 10.1097/01.tp.0000147463.92625.14. Transplantation. 2005. PMID: 15665759 Review. No abstract available.
• Development of a novel drug for transplantation: current results and future perspectives.

  Schorlemmer HU. Schorlemmer HU. Transplant Proc. 2001 May;33(3):2425-8. doi: 10.1016/s0041-1345(01)02060-7. Transplant Proc. 2001. PMID: 11377581 Review. No abstract available.